DAY ONE AND SERVIER FINISH ENROLLMENT IN KEY PHASE 3 FIREFLY-2 TRIAL OF TOVORAFENIB FOR FRONT-LINE TREATMENT OF PEDIATRIC LOW-GRADE GLIOMA (PLGG)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 08 2026
0mins
Source: moomoo
Enrollment Completion: Day One and Servier have completed enrollment for the Phase 3 trial of Tovorafenib, a treatment for pediatric low-grade glioma (PLGG).
Trial Focus: The trial aims to evaluate the efficacy and safety of Tovorafenib as a frontline treatment for children diagnosed with PLGG.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
